Explore Bayer
Core profile pages, annual revenue records, and related research hubs for this company.
Leadership History
3 leaders · Full leadership timeline
Bayer began as a dyestuffs manufacturer in 1863 and became one of Germany's defining life-sciences companies. The same breadth that once made Bayer resilient now creates complexity: drug development, consumer brands, and agricultural technology each require different capital cycles, regulation, and risk tolerance.
Bayer's business model combines regulated prescription medicines, over-the-counter consumer health brands, and agricultural inputs. Pharmaceuticals sells prescription products and earns licensing income; Consumer Health sells self-care brands through retail and pharmacy channels; Crop Science sells seeds, traits, herbicides, fungicides, insecticides, and digital agriculture solutions to growers and distributors.
Chief Executive Officer and Chairman of the Board of Management
Anderson is leading Bayer's Dynamic Shared Ownership restructuring, debt reduction agenda, and portfolio reset while managing litigation and patent-cycle pressure.
Former Chairman of the Board of Management
Baumann led Bayer through the Monsanto acquisition, a strategically transformative but legally and financially burdensome deal.
Historical Chairman and Managing Director
Duisberg helped turn Bayer from a regional dyestuffs business into an international chemical and pharmaceutical company.
Bayer faces overlapping challenges: Roundup litigation, net financial debt, commodity-like pressure in glyphosate, Xarelto generic erosion, and the operational difficulty of changing a large German conglomerate's management model while preserving scientific productivity.
William N. (Bill) Anderson is CEO and Chairman of the Board of Management of Bayer AG.
Bill Anderson's priority is simplifying Bayer's organization, reducing debt, rebuilding pharma growth, and restoring investor confidence.
The Board of Management runs Bayer under a German governance model, with division leaders accountable for Pharmaceuticals, Consumer Health, and Crop Science.
Bayer is focused on cost simplification through Dynamic Shared Ownership, disciplined capital allocation, pharmaceutical launch execution, and Crop Science margin recovery.
The leadership risk is execution fatigue: the turnaround requires cost cuts, litigation management, innovation, and cultural change at the same time.